Elicio is merging with Angion Biomedica, a Uniondale, NY-based biotech that began searching for strategic alternatives last July after Phase II setbacks forced it to shutter all R&D work.

In 2021, PepGen raised $113 million to challenge Sarepta in DMD and build its neuromuscular and neurologic pipeline.

AbbVie has tapped Immunome’s discovery platform in a heavily backended partnership and option agreement in a bid to discover 10 antibody-target pairs from three as-yet-unnamed tumor types.

French-American biotech Amolyt Pharma has raised a €130 million ($138 million) Series C round, planning to use the cash to take its hypoparathyroidism drug into final-stage testing and move another experimental drug into the clinic.

Brian Wiley, chief business officer at Portage Biotech, spoke of striking a balance between in-person and virtual meetings.

Biotech company F2G announced today the FDA has accepted its NDA filing for its antifungal therapy, Olorofim. The FDA has set the Prescription Drug User Fee Act (PDUFA) date for June 17, 2023.

Seattle-based biotech EMulate Therapeutics is working hard on the latter, developing technology that leverages magnetic fields to emulate the information inherent to therapeutic molecules and replicate their therapeutic effects without ever administering the molecules to patients.

Drug developers are designing new psychedelic compounds to treat depression and other mental-health conditions but skip the trip.